Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in syncytiotrophoblasts | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 557 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10737
Sealed predictions
- CYP2J2 in oligodendrocytes, braak+0.10 (p 0.802) → +0.36 (p 0.336)receipt 10744
- CYP2J2 in dopamine neurons, braak-0.27 (p 0.474) → +0.58 (p 0.105)receipt 10745
Swarm cases
receipt 10745: CYP2J2 in dopamine neurons, braak
- power
- full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.874, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.17, sign flips 10; without severely affected donors +0.01 (p 0.962, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP2J2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 10744: CYP2J2 in oligodendrocytes, braak
- power
- full sample +0.26 (p 0.306, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.360, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range +0.16 to +0.39, sign flips 0; without severely affected donors +0.26 (p 0.306, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP2J2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts